STAT July 23, 2024
Following the release of widely touted study results for a Gilead Sciences HIV treatment, a new analysis finds the medicine — called lenacapavir — could be made for as little as $26 to $40 per person each year, which the researchers argue could alleviate concerns about limited access in many countries.
The medicine drew considerable attention last month after a late-stage clinical trial found that twice-a-year injections completely protected cisgender women from contracting HIV. None of the 2,134 women who received lenacapavir contracted the virus, while 16 of 1,068 women who...
Today's Sponsors
Today's Sponsor